Prevalence of Non-alcoholic Fatty Liver Disease and its Association with Chronic Kidney Disease among Type-2 Diabetic Patients with the help of Ultrasonography
DOI:
https://doi.org/10.17720/bxr16n40Keywords:
Type-2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD), Chronic Kidney Disease (CKD), Ultrasound.Abstract
The primary aim of our study was to investigate whether an association exists between chronic kidney disease (CKD) and the heightened severity of Non-alcoholic fatty liver disease (NAFLD) among individuals diagnosed with type-2 diabetes. Building upon previous research suggesting a potential connection, we undertook a cross-sectional study using non-probability sampling over a three-month period from July to September 2023 at Life Care Lab and Medical Diagnostic Center Rawalpindi. Our study encompassed Type-2 diabetic patients, regardless of age or gender, and focused on determining the grade of fatty liver disease through ultrasonographic assessments, categorized as Grade 1, 2, or 3. Notably, our study exclusively enrolled Type-2 diabetics who developed fatty liver disease in the absence of alcohol consumption, specifically excluding those whose fatty liver disease resulted from other causes such as Hepatitis B & C, Jaundice, or drug-related factors. Chronic kidney disease was defined based on various parameters, including glomerular filtration rate (GFR), Urine AlbuminCreatinine ratio (UACR), and Hemoglobin A1c levels. Importantly, we excluded patients with kidney disease attributable to factors other than diabetes. Our study cohort consisted of 300 Type-2 diabetes patients, comprising 63% males and 37% females. We categorized them into four age groups: 35-45 years, 46-55 years, 56-65 years, and >66 years. From the total population of our study there are 28% patients of chronic kidney disease and 54% have Nonalcoholic fatty liver disease while there were a 58% individuals of CKD who were suffering from NAFLD. To analyze our findings, we employed statistical tools within SPSS, revealing a Chi-square prevalence value of p = 0.034. This value strongly indicates the existence of a relationship between Non-alcoholic fatty liver disease and chronic kidney disease in Type-2 diabetics. Furthermore, our results suggest that these patients often share few things in common that elevate their susceptibility to these conditions like advanced age, a higher grade of fatty liver disease. This research sheds light on the intricate interplay between CKD, NAFLD, and Type-2 diabetes, offering valuable insights for both clinical practice and future investigations in this field.
Downloads
References
Olokoba AB, Obateru OA, Olokoba LBJOmj. Type 2 diabetes mellitus: a review of current trends. 2012;27(4):269.
Akash MSH, Rehman K, Chen SJJocb. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. 2013;114(3):525-31.
Padhi S, Nayak AK, Behera AJB, Pharmacotherapy. Type II diabetes mellitus: a review on recent drug based therapeutics. 2020;131:110708.
Powell EE, Wong VW-S, Rinella MJTL. Non-alcoholic fatty liver disease. 2021;397(10290):2212-24.
Leite NC, Salles GF, Araujo AL, Villela‐Nogueira CA, Cardoso CRJLi. Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus. 2009;29(1):113-9.
Bellentani S, Scaglioni F, Marino M, Bedogni GJDd. Epidemiology of non-alcoholic fatty liver disease. 2010;28(1):155-61.
Lazo M, Clark JM, editors. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in liver disease; 2008: © Thieme Medical Publishers.
Levey AS, Coresh JJTl. Chronic kidney disease. 2012;379(9811):165-80.
El Nahas AM, Bello AKJTl. Chronic kidney disease: the global challenge. 2005;365(9456):331-40.
Thomas R, Kanso A, Sedor JRJPcCiop. Chronic kidney disease and its complications. 2008;35(2):329-44.
Shung KKJJMBE. Diagnostic ultrasound: Past, present, and future. 2011;31(6):371-4.
Esterson YB, Grimaldi GMJCild. Radiologic imaging in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2018;22(1):93-108.
Oh M, Winn J, Poordad FJAp, therapeutics. diagnosis and treatment of non‐alcoholic fatty liver disease. 2008;28(5):503-22.
Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi AJAp. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. 2007;96(4):542-7.
Petrick A, Benotti P, Wood GC, Still CD, Strodel WE, Gabrielsen J, et al. Utility of ultrasound, transaminases, and visual inspection to assess nonalcoholic fatty liver disease in bariatric surgery patients. 2015;25:2368-75.
Pirmoazen AM, Khurana A, El Kaffas A, Kamaya AJT. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. 2020;10(9):4277.
Mantovani A, Turino T, Lando MG, Gjini K, Byrne C, Zusi C, et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. 2020;46(4):296-303.
Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. 2008;51:444-50. 41
Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora EJJoh. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? 2011;54(5):1020-9.
Kanwal S, Ghaffar T, Aamir AH, Usman KJPJoMS. Frequency of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus and its associated risk factors. 2021;37(5):1335.
Jenks S, Conway B, Hor T, Williamson R, McLachlan S, Robertson C, et al. Hepatic steatosis and non‐alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes. 2014;31(9):1039-46.
Sirota JC, McFann K, Targher G, Chonchol M, Jalal DIJAjon. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988–1994. 2012;36(5):466-71.
Zhao P, Yan J, Pan B, Liu J, Fu S, Cheng J, et al. Association between the risk of non-alcoholic fatty liver disease in patients with type 2 diabetes and chronic kidney disease. 2022:1141-51.
Ali A, Amin MJ, Ahmed MU, Taj A, Aasim M, Tabrez EJPJoMS. Frequency of nonalcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics. 2022;38(1):28.
Singh G, Nepalia S, Rijhwani PJIJoRiMS. Association of non-alcoholic fatty liver disease with chronic kidney disease in Type 2 diabetes mellitus. 2019;7(4):1296.
Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, et al. Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. 2015;10(11):e0142808.
Lee Y-J, Wang C-P, Hung W-C, Tang W-H, Chang Y-H, Hu D-W, et al. Common and unique factors and the bidirectional relationship between chronic kidney disease and nonalcoholic fatty liver in type 2 diabetes patients. 2020;13:1203.
Adrian T, Hornum M, Knop FK, Almdal T, Rossing P, Heinrich NS, et al. Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease. 2023:1-12.
Hossein-Panah F, Sadeghi L, Rambod M, Foroutan M, Naseri MJRiM. Assessing predicting factors in non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes. 2006;30(1):9-15.
Aubert L, Sandino J, Gutiérrez-Solís E, García-Martín F, Segura J, Porrini E, et al. Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus. 2022;37(6):1125-
Seo DH, Suh YJ, Cho Y, Ahn SH, Seo S, Hong S, et al. Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. 2022;46(4):630-9.
Herath HMM, Kodikara I, Weerarathna TP, Liyanage GJD, Research MSC, Reviews. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study. 2019;13(1):246-50.
Atan NAD, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and metaanalysis. 2017;10(Suppl1):S1. 42
Silaghi CA, Silaghi H, Colosi HA, Craciun AE, Farcas A, Cosma DT, et al. Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. 2016;89(1):82.
Yi M, Chen RP, Yang R, Chen HJDM. Increased prevalence and risk of non‐ alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. 2017;34(4):505-13.
Heidari Z, Gharebaghi AJJoc, JCDR dr. Prevalence of non alcoholic fatty liver disease and its association with diabetic nephropathy in patients with type 2 diabetes mellitus. 2017;11(5):OC04.
Sun Y, Hong L, Huang Z, Wang L, Xiong Y, Zong S, et al. Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients. 2022;107(9):e3661-e9.
Ahn A-L, Choi J-K, Kim M-N, Kim S-A, Oh E-J, Kweon H-J, et al. Non-alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 years or older. 2013;34(3):199.
Angulo PJNEJoM. Nonalcoholic fatty liver disease. 2002;346(16):1221-31.
Adams LA, Harmsen S, Sauver JLS, Charatcharoenwitthaya P, Enders FB, Therneau T, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. 2010;105(7):1567.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
